Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Chronic Myeloid Leukemia (CML)

Study type: Observational

Funder types: Industry

Identifiers

NCT02363868

CA180-568

Details and patient eligibility

About

The purpose of this study is to examine the healthcare costs among patients with CML receiving dasatinib or nilotinib as first line therapy in a commercially or Medicare insured population.

Enrollment: 186 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Age >18 years
• International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9 CM) code for CML (205.1x)
• At least 2 prescriptions for dasatinib or nilotinib from July 1, 2008 to June 31, 2013
• Continuous eligibility for the 6 months pre- and post-index date (defined as the date of first fill for dasatinib or nilotinib)

Exclusion Criteria:

• History of bone marrow or stem cell transplant as identified in the 6 month pre-period

Trial design

186 participants in 2 patient groups

CML subjects receiving Dasatinib

Description:

CML receiving dasatinib as first or second line therapy will be conducted to assess healthcare costs

CML subjects receiving Nilotinib

Description:

CML receiving nilotinib as first or second line therapy will be conducted to assess healthcare costs